BioSante (Nasdaq: BPAX) 66.5% LOWER; says Libegel did not meet primary, secondary endpoints. Click here to see the full report.
Novellus Systems (Nasdaq: NVLS) 19% HIGHER; Novellus and Lam Research to combine in a $3.3 billion all stock deal.
Novellus holders to get 1.125 Lam shares.